Proteostasis Therapeutics Inc (NASDAQ:PTI) major shareholder Cormorant Asset Management, Ll sold 504,027 shares of Proteostasis Therapeutics stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $4.88, for a total transaction of $2,459,651.76. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Shares of Proteostasis Therapeutics Inc (PTI) opened at $5.02 on Wednesday. Proteostasis Therapeutics Inc has a 1-year low of $1.41 and a 1-year high of $16.67.

Proteostasis Therapeutics (NASDAQ:PTI) last announced its quarterly earnings data on Tuesday, November 14th. The company reported ($0.56) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.16. The firm had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.38 million. Proteostasis Therapeutics had a negative net margin of 712.49% and a negative return on equity of 93.15%. analysts anticipate that Proteostasis Therapeutics Inc will post -2.47 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the company. LMR Partners LLP bought a new stake in shares of Proteostasis Therapeutics in the 2nd quarter worth approximately $127,000. Goldman Sachs Group Inc. raised its holdings in Proteostasis Therapeutics by 364.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 51,911 shares of the company’s stock valued at $243,000 after buying an additional 40,731 shares during the last quarter. Susquehanna International Group LLP bought a new stake in Proteostasis Therapeutics during the 2nd quarter valued at $254,000. Dimensional Fund Advisors LP bought a new stake in Proteostasis Therapeutics during the 2nd quarter valued at $296,000. Finally, Sabby Management LLC raised its holdings in Proteostasis Therapeutics by 109.6% during the 2nd quarter. Sabby Management LLC now owns 125,151 shares of the company’s stock valued at $586,000 after buying an additional 65,451 shares during the last quarter. Hedge funds and other institutional investors own 68.03% of the company’s stock.

A number of brokerages have recently weighed in on PTI. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Proteostasis Therapeutics in a report on Tuesday. Leerink Swann boosted their price objective on shares of Proteostasis Therapeutics from $6.00 to $8.00 in a report on Tuesday, December 12th. Robert W. Baird boosted their price objective on shares of Proteostasis Therapeutics from $13.00 to $25.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. Finally, Zacks Investment Research lowered shares of Proteostasis Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 18th.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/cormorant-asset-management-ll-sells-504027-shares-of-proteostasis-therapeutics-inc-pti-stock/1773916.html.

About Proteostasis Therapeutics

Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.

Insider Buying and Selling by Quarter for Proteostasis Therapeutics (NASDAQ:PTI)

Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.